Spondyloarthritiden (SpA) sind entzündlich rheumatische Erkrankungen, die durch
Entzündungen im Bereich der Wirbelsäule gekennzeichnet sind, welche häufig zu …

Background: Biologics and small-molecule drugs have become increasingly accepted
worldwide in the treatment of axial spondyloarthritis (axSpA), including ankylosing …

Objective This study assessed the efficacy and safety of secukinumab and adalimumab in
patients with active ankylosing spondylitis (AS). Methods A Bayesian network meta-analysis …

Introduction Recent changes to treatment guidelines for ankylosing spondylitis (AS) have
listed first-line advanced therapies as tumor necrosis factor (TNF), interleukin (IL)-17, and …

The purposes of this study were to determine the prevalence of metabolic syndrome (MetS)
in patients with ankylosing spondylitis (AS) receiving anti-TNFα therapy and evaluate the …

Esculetin (6, 7-dihydroxycoumarin) is a coumarin derivative extracted from natural plants
and has been reported to have anticancer activity. However, the mechanism by which …

Background: Biologic treatments have enhanced the treatment outcomes of patients with
active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only …

Aim To compare the cost‐effectiveness of secukinumab vs adalimumab at 1 and 2 years of
treatment in patients with ankylosing spondylitis (AS) by analyzing the cost per responder …

We all consider the “comparative effectiveness” of available treatment options in daily
clinical practice, knowingly or unknowingly. In fact, that and “comparative safety” are 2 of our …

Objective: to conduct a cost-effectiveness study of major biologic disease-modifying
antirheumatic drugs (bDMARDs) used for the treatment of ankylosing spondylitis (AS) in …